IL2 and neoplasm: Similar to the profiles obtained by ELISpot and ELISA, we saw decreased levels of induction of CD54 and MHC-class I on tumor cells by supernatants of patients as compared to those from the healthy individuals when the NK cells were treated with the combination of IL-2 and anti-CD16 mAbs.